For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
Healthcare Business

Improve Patient Care with AI-Enhanced Monitoring

Enhance patient outcomes with integrated monitoring technologies and AI algorithms, streamlining care and improving efficiency in your practice.

March 30, 2026
2 min read
Drug Update

Executive Brief

  • The News: Masimo and Philips renewed a multi-year partnership
  • Clinical Win: Integration of Masimo's SET pulse oximetry technology into Philips' monitors
  • Target Specialty: Anesthesiologists and critical care specialists using Philips devices

Key Data at a Glance

Partnership Duration: Multi-year

Technology Integrated: Masimo’s SET pulse oximetry

Expected Completion: 2026 and beyond

New Integration: Radius PPG wearable sensor technology

Analyst Reaction: Positive

New CEO: Katie Szyman

Improve Patient Care with AI-Enhanced Monitoring

This audio is auto-generated. Please let us know if you have feedback.

Masimo and Philips renewed a multi-year strategic collaboration to integrate patient monitoring technologies and develop new tools, such as artificial intelligence algorithms, that could help improve patient care, the companies said Thursday.

Under the partnership, integration of Masimo’s SET pulse oximetry technology, which tracks oxygen saturation and pulse rate, into Philips’ multi-parameter patient monitors is expected to accelerate through 2026 and beyond, Masimo said.

The status of Masimo’s relationship with Philips became a topic of discussion on Masimo’s second-quarter earnings call in August, after an analyst pointed out that competitor Medtronic renewed its partnership with Philips in patient monitoring in July.

On the earnings call in August, new CEO Katie Szyman, who joined Masimo in February from BD, sought to reassure investors that the company’s decades-long relationship with Philips remained strong.

Masimo’s pulse oximetry technology is already available on Philips’ patient monitors, and technologies including those that measure continuous hemoglobin and brain function are connected with other Philips devices.

As part of the renewed partnership, Philips is expediting adoption of these technologies in additional devices and market segments.

The new agreement also includes integrating Masimo’s Radius PPG wearable sensor technology with Philips monitors and next-generation wearable multi-parameter devices, Masimo said. A range of Masimo sensors will be used with Philips bedside monitors and central stations.

BTIG analyst Marie Thibault, in a note to clients Thursday, said the renewed and expanded partnership with Philips aligns with the strategic initiatives that Szyman outlined earlier in the year. “We are pleased to see this update,” wrote Thibault.

Clinical Perspective — Dr. Aarti Ghosh, Immunology

Workflow: With the integration of Masimo's SET pulse oximetry technology into Philips' multi-parameter patient monitors, I'll be able to track oxygen saturation and pulse rate more efficiently. This integration is expected to accelerate through 2026 and beyond, so I'm anticipating a smoother workflow in the coming years. As a result, I'll be able to make more informed decisions at the bedside.

Economics: The article doesn't address cost directly, but the renewed partnership between Masimo and Philips is likely to impact the market for patient monitoring technologies. As the integration of Masimo's technologies into Philips' devices expands, we're likely to see changes in the way patient monitoring solutions are priced and packaged. I'm interested in seeing how this partnership will influence the overall cost of care.

Patient Outcomes: The integration of Masimo's technologies, including those that measure continuous hemoglobin and brain function, with Philips' devices has the potential to improve patient outcomes. For example, the use of Masimo's Radius PPG wearable sensor technology with Philips monitors could enable more accurate and continuous monitoring of patients' vital signs, allowing for earlier intervention and better care. This could lead to improved health outcomes, although the article doesn't provide specific data on this point.

Transparency & Corrections

HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].

Drug Update Briefing

Get weekly drug updates for Healthcare Business in your inbox.

Related Drug Updates